[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100502347":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":11,"centralContacts":29,"locations":39,"responsibleParty":56,"collaborators":11,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":11,"eligibilityCriteria":66,"healthyVolunteers":62,"sex":67,"minAge":68,"maxAge":69,"enrollmentInfo":70,"targetDuration":11,"studyType":73,"phases":74,"briefSummary":77,"conditions":78,"keywords":11,"overallStatus":42,"whyStopped":11,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"October 6 University","OTHER",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Prednisolone","ACTIVE_COMPARATOR",null,[13],"Drug: Prednisolone",{"label":15,"type":10,"description":11,"interventionNames":16},"Cerebrolysin",[17],"Drug: Cerebrolysin",{"label":19,"type":10,"description":11,"interventionNames":20},"Prednisolone and Cerebrolysin",[13,17],[22,26],{"type":23,"name":9,"description":24,"armGroupLabels":25,"otherNames":11},"DRUG","prednisolone 60mg tablet once daily for 5 days then tapering dose",[9,19],{"type":23,"name":15,"description":27,"armGroupLabels":28,"otherNames":11},"intramuscular Cerebrolysin 10 mg daily for 3 weeks",[15,19],[30,35],{"name":31,"role":32,"phone":33,"phoneExt":11,"email":34},"Engy Wahsh","CONTACT","01003095692","engywahsh@o6u.edu.eg",{"name":36,"role":32,"phone":37,"phoneExt":11,"email":38},"mohamed rez","01006904056","Abdelmaksodm.mousa@hotmail.com",[40],{"facility":41,"status":42,"city":43,"state":11,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"October 6 university hospital","RECRUITING","Giza","12573","Egypt","EG",{"type":48,"coordinates":49},"Point",[50,51],31.20861,30.00944,{"lat":51,"lon":50},[54],{"name":55,"role":32,"phone":11,"phoneExt":11,"email":11},"Abdelmaksod Mohammed Mousa, MD",{"type":57,"investigatorFullName":58,"investigatorTitle":59,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","engy wahsh","LECTURER OF CLINICAL PHARMACY","100502347","phase-1-efficacy-of-prednisolone-versus-cerebrolysin-in-the-treatment-of-bells-palsy-100502347",false,"NCT05821075","Efficacy of Prednisolone Versus Cerebrolysin in the Treatment of Bell's Palsy","Comparative Study Between Prednisolone, Cerebrolysin in the Treatment of Bell's Palsy","Inclusion Criteria:\n\n* unilateral acute facial palsy of no identifiable cause\n\nExclusion Criteria:\n\n* Recurrent facial Bell's palsy\n* Pregnancy\n* Diabetes\n* Epilepsy\n* Severe hypertension,\n* Renal or hepatic disease,\n* Gastric or duodenal ulcer\n* presence of acute otitis media or ipsilateral chronic otitis\n* Recent head injury,\n* psychiatric disease\n* If there is any contraindications for corticosteroids","ALL","18 Years","60 Years",{"count":71,"type":72},90,"ESTIMATED","INTERVENTIONAL",[75,76],"PHASE1","PHASE2","Bell's palsy, a peripheral facial nerve paresis, is the most common disorder of the facial nerve and one of the most common mononeuropathies.\n\nMany patients with Bell's palsy will develop some complications such as synkinesis, crocodile tears and 'sweating' of the ear while eating Commonly used medications to treat Bell's palsy is Corticosteroids Cerebrolysin stimulates the regeneration of the nervous tissue with protective action we aim to study the efficacy of cerebrolycin in Bell's palsy",[79],"Bell Palsy","2025-07-28",{"date":82,"type":83},"2025-07-31","ACTUAL",{"date":85,"type":83},"2023-08-24",{"date":87,"type":72},"2026-02",{"name":5,"class":6},1]